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Background
HIV-1 transmission occurs predominantly through muco-
sal surfaces. In macaque models of SHIV mucosal trans-
mission, passive administration of the monoclonal
neutralizing antibody IgG1 b12 (b12) can protect against
virus infection. However, an Fc variant of b12, deficient in
FcgR and complement binding, (LALA) had diminished
protective capacity. Concentrations and kinetics of b12
and LALA in serum and in mucosal secretions were deter-
mined in the protection studies, but the biodistribution
and kinetics of the antibodies in mucosal and lymphatic
tissues and around the site of viral challenge have not
been assessed.
Methods
We conducted a pilot study to develop protocols to pro-
cess macaque tissue specimens and to detect and quantify
passively transferred neutralizing antibodies (NAbs) in tis-
sue homogenates. To confirm that transport of LALA to
the site of challenge was not altered from that of b12, we
obtained secretions and tissue specimens from rhesus
macaques that had been passively infused with either b12
or LALA at 24 hours prior to necropsy, matching the time
of challenge in the protection study.
Results
We quantified passively administered b12 and LALA in
a variety of macaque mucosal and lymphoid tissues and
assessed the neutralization capacity of the NAbs loca-
lized in vaginal and rectal sites typically exposed to virus
in challenge studies. We demonstrated that the rapid
distribution and broad delivery to lymphoid and muco-
sal tissues of both b12 and LALA are equivalent.
Conclusion
We developed and utilized a methodology to evaluate the
transudation of transferred antibody into mucosal and
lymphatic tissues and showed that the reduction in the
protective capacity of LALA compared to b12 cannot be
attributed to a differential effect of biodistribution. This
methodology will be useful to describe the pharmacoki-
netics of newly discovered MAbs and may inform about
the characteristics of therapeutic antibodies or antibodies
to elicit by vaccination.
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